169 related articles for article (PubMed ID: 33575859)
1. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.
Parkes A; Wang WL; Patel S; Leung CH; Lin H; Conley AP; Somaiah N; Araujo DM; Zarzour M; Livingston JA; Ludwig J; Roland CL; Ravi V; Benjamin RS; Ratan R
Breast Cancer Res Treat; 2021 Apr; 186(3):871-882. PubMed ID: 33575859
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Frezza AM; Jones RL; Lo Vullo S; Asano N; Lucibello F; Ben-Ami E; Ratan R; Teterycz P; Boye K; Brahmi M; Palmerini E; Fedenko A; Vincenzi B; Brunello A; Desar IME; Benjamin RS; Blay JY; Broto JM; Casali PG; Gelderblom H; Grignani G; Gronchi A; Hall KS; Mir O; Rutkowski P; Wagner AJ; Anurova O; Collini P; Dei Tos AP; Flucke U; Hornick JL; Lobmaier I; Philippe T; Picci P; Ranchere D; Renne SL; Sbaraglia M; Thway K; Wagrodzki M; Wang WL; Yoshida A; Mariani L; Kawai A; Stacchiotti S
JAMA Oncol; 2018 Sep; 4(9):e180219. PubMed ID: 29800950
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses.
Palassini E; Mir O; Grignani G; Vincenzi B; Gelderblom H; Sebio A; Valverde C; Baldi GG; Brunello A; Cardellino GG; Marrari A; Badalamenti G; Martin-Broto J; Ferraresi V; Libertini M; Turano S; Gataa I; Collini P; Tos APD; Gennaro M; Bini F; Provenzano S; Vullo SL; Mariani L; Le Cesne A; Casali PG
Breast Cancer Res Treat; 2022 Apr; 192(3):603-610. PubMed ID: 35150367
[TBL] [Abstract][Full Text] [Related]
4. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
[TBL] [Abstract][Full Text] [Related]
6. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Stacchiotti S; Van der Graaf WTA; Sanfilippo RG; Marreaud SI; Van Houdt WJ; Judson IR; Gronchi A; Gelderblom H; Litiere S; Kasper B
Cancer; 2022 Aug; 128(15):2932-2938. PubMed ID: 35561319
[TBL] [Abstract][Full Text] [Related]
7. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center.
Lu Q; Lee K; Xu F; Xia W; Zheng Q; Hong R; Jiang K; Zhai Q; Li Y; Shi Y; Yuan Z; Wang S
Cancer Commun (Lond); 2020 May; 40(5):222-233. PubMed ID: 32390331
[TBL] [Abstract][Full Text] [Related]
8. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
9. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
10. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Zhang J; Lin Y; Sun XJ; Wang BY; Wang ZH; Luo JF; Wang LP; Zhang S; Cao J; Tao ZH; Wu J; Shao ZM; Yang WT; Hu XC
Ann Oncol; 2018 Aug; 29(8):1741-1747. PubMed ID: 29905759
[TBL] [Abstract][Full Text] [Related]
11. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Ann Oncol; 2016 Feb; 27(2):256-62. PubMed ID: 26578730
[TBL] [Abstract][Full Text] [Related]
12. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
13. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Vernieri C; Milano M; Mennitto A; Maggi C; Ferrari B; Rinaldi L; Mennitto R; Stefanetti C; Re B; Mariani G; Bianchi G; Capri G; de Braud F
Breast Cancer Res Treat; 2017 Sep; 165(2):365-373. PubMed ID: 28616768
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
He K; Wang X; Guan X; Yu Q; Ma Q; Liu Z; Yu Z
Anticancer Res; 2017 Oct; 37(10):5647-5653. PubMed ID: 28982882
[TBL] [Abstract][Full Text] [Related]
16. Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma.
Verschoor AJ; Speetjens FM; Dijkstra PDS; Fiocco M; van de Sande MAJ; Bovée JVMG; Gelderblom H
Oncologist; 2020 Apr; 25(4):e716-e721. PubMed ID: 32297446
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Therapeutic Efficacy of the Early and the Delayed Use of Vinorelbine-Based Regimens for Patients with Advanced Breast Cancer.
Wang Y; Liu J; Jia W; Li S; Rao N; Su F; Liu Q; Yao H
Chemotherapy; 2017; 62(1):71-79. PubMed ID: 27648841
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Gounder MM; Merriam P; Ratan R; Patel SR; Chugh R; Villalobos VM; Thornton M; Van Tine BA; Abdelhamid AH; Whalen J; Yang J; Rajarethinam A; Duh MS; Bobbili PJ; Huynh L; Totev TI; Lax AK; Agarwal S; Demetri GD
Cancer; 2021 Apr; 127(8):1311-1317. PubMed ID: 33296083
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.
Frezza AM; Ravi V; Lo Vullo S; Vincenzi B; Tolomeo F; Chen TW; Teterycz P; Baldi GG; Italiano A; Penel N; Brunello A; Duffaud F; Hindi N; Iwata S; Smrke A; Fedenko A; Gelderblom H; Van Der Graaf W; Vozy A; Connolly E; Grassi M; Benjamin RS; Broto JM; Grignani G; Jones RL; Kawai A; Tysarowski A; Mariani L; Casali PG; Stacchiotti S
Cancer Med; 2021 Apr; 10(8):2645-2659. PubMed ID: 33713582
[TBL] [Abstract][Full Text] [Related]
20. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
